The p53 oncosuppressor protein is subject to negative regulation by MDM2, which efficiently inhibits its activity through an autoregulatory loop. In response to stress, however, p53 undergoes post-translational modifications that allow the protein to escape MDM2 control, accumulate, and become active. Recent studies have shown that, following DNA damage, the HIPK2 serine/ threonine kinase binds and phosphorylates p53, inducing p53 transcriptional activity and apoptotic function. Here, we investigated the role of HIPK2 in the activation of p53 in the presence of MDM2. We found that HIPK2 rescues p53 transcriptional activity overcoming MDM2 inhibition, and that restoration of this p53 function induces apoptosis. Recovery of p53-dependent apoptosis is achieved by preventing p53 nuclear export and ubiquitination mediated by MDM2 in vitro and in vivo following genotoxic stress. These results shed new light on the mechanisms by which the HIPK2/p53 pathway promotes apoptosis and suppression of tumorigenesis.
Introduction
The tumor suppressor p53 is important in the cellular response to genotoxic damage. In normal cells, p53 is present at low concentration and is kept silent. Following stress stimuli, such as hypoxia or DNA damage, p53 accumulates in the nucleus and becomes activated inducing several different responses such as growth arrest, senescence, apoptosis, and DNA repair (Giaccia and Kastan, 1998; Lakin and Jackson, 1999; Prives and Hall, 1999) . These activities contribute to the role of p53 as oncosuppressor by preventing the establishment of mutations in future generation of cells (Gottlieb and Oren, 1996) . The activation of p53 protein occurs at multiple levels including protein stabilization, nuclear accumulation, and post-translational modifications (Appella and Anderson, 2001 ). The biological effects of p53 are largely due to its sequence-specific binding to DNA and transcriptional activation of genes involved in cellcycle regulation and apoptosis (Gottlieb and Oren, 1996) . The transactivation domain of p53 is located at the N-terminus of the protein, interacts with components of the basal transcription machinery, and promotes the transcription of genes containing p53-binding sequences (Unger et al., 1992; Lu and Levine, 1995) . How p53 activation and stabilization occur following stress is still not completely understood.
A loss of p53 function, either by mutations or by deregulation of regulatory proteins, is often detrimental, leading to tumor development and progression (Valculescu and El Deiry, 1996; Vogt Sionov and Haupt, 1999) . One of the key regulatory elements of p53 is mdm2, a cellular proto-oncogene (Oliner et al., 1992) . MDM2 restrains p53 function by concealing its transcriptional activation domain, thereby inhibiting p53-mediated transactivation (Momand et al., 1992) . MDM2 is also able to induce p53 nuclear export, preventing the access of p53 to DNA (Freedman and Roth et al., 1998; Tao and Levine, 1999) . Finally, MDM2 is an E3-ubiquitin ligase able to target p53 for ubiquitination and rapid degradation via proteasome (Haupt et al., 1997; Kubbutat et al., 1997) . The expression of the mdm2 gene is regulated by p53 itself in a negative feedback loop (Barak et al., 1993; Wu et al., 1993) . It is worth noting that the mdm2 gene is amplified in a significant proportion of human tumor types, thereby contributing to tumor development by efficiently reducing the availability of a functional p53 protein (Oliner et al., 1992; Momand et al., 1998) . The MDM2-negative regulation of p53 protein can be neutralized by partner proteins and by specific protein modifications. Several studies have shown that phosphorylation of the p53 protein can regulate its functions in vivo and in vitro (Appella and Anderson, 2001 ). In particular, DNA-damage-induced phosphorylation of serine and threonine residues at the N-terminus contributes to p53 stability by preventing MDM2 from degrading it (Shieh et al., 1997; Unger et al., 1999) . It is quite evident that one way to stabilize and activate p53 in response to stress is by interfering either with the interaction between MDM2 and p53 or with the ability of MDM2 to target bound p53 for degradation. The mechanisms of p53 stabilization and activation are, however, more complex and might also involve stressinduced modification of MDM2 and post-translational modifications of other interacting proteins (Appella and Anderson, 2001) .
Several kinases have been identified that detect genotoxic stress and initiate signaling pathways through p53 phosphorylation (Fuchs et al., 1998; Appella and Anderson, 2001) . A series of different phosphorylation sites in the p53 protein are presumed to be involved in p53 oncosuppressing functions (Siliciano et al., 1997) . A novel serine/threonine kinase, namely HIPK2, has been recently shown to activate the p53 protein through its direct binding and phosphorylation at residue Ser46 (D'Orazi et al., 2002; Hofmann et al., 2002) . Phosphorylation at this site is a late event after severe DNA damage and specifically regulates p53-induced apoptosis (Bulavin et al., 1999; Oda et al., 2000b) . We have recently found that HIPK2 can trigger p53-mediated apoptosis through phosphorylation of p53 at Ser46 after treatment with the chemotherapeutic drug cisplatin; this finding supports a key role for HIPK2 in the stimulation of p53 in response to genotoxic stress (Di Stefano et al., 2004) . Recently, exogenous HIPK2 overexpression was shown to correlate with the reduction of MDM2 protein levels (Wang et al., 2001) . Since MDM2 is the major player in p53-negative regulation and HIPK2 is a positive regulator of p53, we investigated the possibility that HIPK2 may antagonize the inhibitory effect of MDM2 on p53. Here, we demonstrate that HIPK2 can efficiently rescue p53 transcriptional activity over MDM2 inhibition. This action of HIPK2 involves the neutralization of MDM2-dependent p53 ubiquitination and nuclear export in vitro and in vivo following DNA damage, with induction of p53 apoptotic function.
Results

HIPK2 abrogates MDM2-mediated repression of p53 transcriptional activity
The nuclear serine-threonine kinase HIPK2 is able to induce p53 transcriptional activity (Wang et al., 2001; D'Orazi et al., 2002; Hofmann et al., 2002; Kim et al., 2002) . To investigate whether HIPK2 has the ability of activate p53 even in the presence of overexpressed MDM2, we used reporter constructs containing the luciferase gene under the control of the bax, PIG3, or Noxa gene promoters (Miyashita and Reed, 1995; Polyak et al., 1997; Oda et al., 2000a) . H1299 cells were cotransfected with various combinations of expression vectors encoding for p53, MDM2, HIPK2, or the HIPK2 kinase dead mutant-K221R (which is not able to phosphorylate p53 at Ser46 and also does not induce p53-mediated transactivation; Wang et al., 2001; D'Orazi et al., 2002; Hofmann et al., 2002) along with the bax-and PIG3-luciferase reporters. As shown in Figure 1a , p53 expression efficiently induced bax activity relative to the empty vector, while cotransfection with MDM2 reduced the ability of p53 to transactivate the reporter construct, consistent with previous studies (Haupt et al., 1997) . HIPK2 expression increased p53-mediated transactivation and strongly rescued the p53 transcriptional activity, in a dose-dependent manner, counteracting the inhibitory effect of MDM2. In contrast to this, K221R failed to neutralize the inhibitory effect of MDM2 (Figure 1a . Consistent with the HIPK2 kinase activity on p53 at Ser46, the transcriptional activity of a p53S46A mutant was not modified by HIPK2 either in the absence or in the presence of MDM2 ( Figure 1d ). We also investigated whether p53 was able to interact with MDM2 in the presence of HIPK2. We transfected H1299 cells with p53, p53 and MDM2, or both together with HIPK2 expression vectors. At 24 h after transfection, cells were lysed and equal amounts of total cell extracts were immunoprecipitated with anti-p53 monoclonal antibodies. Figure 1e shows that MDM2 was no longer able to interact with p53 in the presence of HIPK2.
Taken together, these results suggest that HIPK2 can rescue p53 transcriptional activity over MDM2 inhibition, and that the HIPK2 kinase domain plays a role in this effect. Moreover, HPK2 is able to change the interaction between MDM2 and p53.
HIPK2 prevents MDM2-mediated p53 nuclear export
The inhibition of p53 function by MDM2 requires, to a larger extent, the nuclear export of p53 (Freedman and Roth et al., 1998; Tao and Levine, 1999) . Thus, we asked whether HIPK2 might interfere with the MDM2-mediated nuclear/cytoplasmic shuttling of p53. To address this question, H1299 cells were cotransfected with vectors expressing p53 in combination with MDM2, HIPK2, and K221R and, 24 h later, fixed and stained for p53 immunofluorescence analysis. As shown in Figure 2 , the proportion of cells with p53 nuclear staining, compared with cells with both nuclear and cytoplasmic staining, was scored for each combination.
Localization of p53 was almost entirely nuclear when expressed alone, but also became cytoplasmic when coexpressed with MDM2 ( Figure 2a ). Indeed, under this condition, the proportion of cells with cytoplasmic staining increased almost four-fold (Figure 2b ), consistent with previous findings (Freedman and Roth et al., 1998; Tao and Levine, 1999) . Interestingly, in the presence of both HIPK2 and MDM2 proteins, p53 was mostly detected in the nuclei (i.e. only 10% of the cells had cytoplasmic staining), as with p53 alone, while, in the presence of both K221R and MDM2, p53 was cytoplasmic in a larger number of cells (Figure 2a and b), indicating that HIPK2 can block MDM2-mediated p53 nuclear export.
HIPK2 attenuates ubiquitination of p53 mediated by MDM2
To investigate whether HIPK2 can interfere with p53 inhibition mediated by MDM2 through the ubiquitinproteasome pathway (Haupt et al., 1997; Kubbutat et al., 1997) , we transfected H1299 cells with p53, p53 and MDM2, or both together with HIPK2 or K221R expression vectors. At 24 h after transfection, cells were either lysed to analyse p53 protein levels by direct Western blotting or treated with the proteasome inhibitor MG132, to prevent p53 degradation, prior to p53 immunoprecipitation from equal amounts of total cell extracts. Figure 3a shows that, in the absence of the proteasome inhibitor MG132, MDM2 was able to degrade p53, as already reported (Haupt et al., 1997) , while HIPK2 overexpression recovered p53 stabilization, even to a larger extent than the p53 overexpressing cells. The catalytically inactive K221R mutant showed an intermediate phenotype, being able to recover partially p53 stabilization. The p53 immunoprecipitation analyses of MG132-treated cells revealed a ladder of p53-specific high molecular weight bands and a smear, indicative of protein ubiquitination, almost exclusively when MDM2 was coexpressed with p53 and, in a lesser extent, when K221R mutant was added (Figure 3b) , consistent with the stabilization results shown in Figure 3a . On the contrary, addition of HIPK2 strongly reduced the extent of p53 ubiquitination. Western blot analysis of the transduced proteins shows a downmodulation of MDM2 protein levels when MDM2 was coexpressed with p53 and HIPK2, as suggested (Wang et al., 2001) (Figure 3b, lower panel) . These results show that HIPK2 protects p53 stabilization by preventing its in vivo ubiquitination by MDM2 and that HIPK2 activities other than the kinase one can be involved in this regulation.
HIPK2 rescues the p53 apoptotic function inhibited by MDM2
The clear effect of HIPK2 on MDM2-mediated inhibition of p53 prompted us to evaluate its biological consequences. One of the most important functions of p53 is induction of apoptosis, and it is well known that MDM2 inhibits it (Chen et al., 1996; Haupt et al., 1996) Figure 2 HIPK2 blocks the nuclear export of p53 by MDM2. (a) H1299 cells were transfected with the indicated combinations of expression vectors, using the lipofectaminePlus method. Subcellular localization of p53, stained using anti-p53 monoclonal antibody DO1, was examined with a fluorescent microscopy. Cells were simultaneously stained for DNA using Hoechst. (b) Summary of p53 localization in stained cells (200-500 cells) from three independent experiments. The staining phenotype was categorized in two groups, one with nuclear p53 staining only and one with nuclear and cytoplasmic staining. The graph shows the percentage of cells with p53 cytoplasmic staining7s.d. whereas HIPK2 induces it (D'Orazi et al., 2002; Hofmann et al., 2002) . To examine whether and to what extent HIPK2 interferes with MDM2 in this process, cell viability was first analysed in H1299 cells transfected with p53, either alone or together with MDM2, and HIPK2 vectors. As shown in Figure 4a , induction of cell death by HIPK2 expression rescued the p53-mediated death inhibited by MDM2 overexpression. Apoptosis was then measured with the TUNEL assay. H1299 cells were transfected with relatively high amount of p53 expression vector, using the efficient lipofectaminePlus transfection method in order to induce at least 15% apoptosis, and with MDM2, HIPK2, and K221R vectors. In agreement with the viability data, we observed a consistent inhibitory effect of MDM2 on p53-induced TUNEL positivity. As shown in Figure 4b , MDM2 reduced the level of p53-mediated apoptosis by 50%, but the inhibition was relieved by coexpression of HIPK2, while the K221R mutant failed to do so. These results suggest that HIPK2 protects p53 apoptotic activity from the inhibitory effect of MDM2 in a kinase-dependent manner.
Inhibition of p53 activity mediated by MDM2 is relieved following cisplatin treatment
To address the physiological relevance of the role played by HIPK2 during p53 activation, despite the presence of MDM2, we took advantage of the recent finding that HIPK2 plays an essential role in inducing p53-dependent apoptosis in response to the antineoplastic drug cisplatin (Kim et al., 2002; Di Stefano et al., 2004) . To this end, RKO cells were transfected with the MDM2 expression vector (to mimic in vivo mdm2 amplification) and 24 h later treated with cisplatin. As shown in Figure 5a , the expression of HIPK2 increased concomitantly to total p53 protein and Ser46 phosphorylation, as reported (Di Stefano et al., 2004) , and remained high despite the presence of MDM2. Interestingly, MDM2 was not able to impair the HIPK2 ability to phosphorylate p53 at Ser46. These results were confirmed on MG132-treated cells, in which p53 is stabilized independent of phosphorylation, indicating that p53 phosphorylation at Ser46 depends on cisplatin treatment, rather than protein accumulation per se (Figure 5b ).
To better elucidate whether the cisplatin-mediated HIPK2 induction could interfere with p53 ubiquitina- Figure 5c , Western blot analysis of total cell extracts revealed that treatment with cisplatin strongly reduced the extent of p53 ubiquitination in the pSuper cells (Figure 5c , in the left panel see the ladder of p53-specific high molecular weight bands detected exclusively in the p53 and MDM2 cotransfected sample). Interestingly, MDM2 overexpression along with treatment with cisplatin was not able to induce p53 ubiquitination. On the contrary, in the HIPK2-interfered cells, p53 was again ubiquitinated by MDM2 as shown by the ladder of p53-specific high molecular weight bands (Figure 5c , right panel). Altogether, these data suggest the requirement of HIPK2 for p53 stabilization after genotoxic damage and MDM2 overexpression.
To investigate whether the cisplatin-mediated HIPK2 induction correlated with its ability of activate p53 apoptotic function, despite the presence of MDM2, we performed a luciferase assay. To this end, RKO cells were transfected with the expression vector encoding for MDM2 along with the bax-, PIG3-, and Noxa-luciferase reporters and treated with cisplatin. As shown in Figure 5d , cisplatin efficiently induced bax-, PIG3-, and Noxa-luciferase activity relative to the untreated cells; interestingly, MDM2 overexpression was not able to inhibit p53-mediated transcription of target genes induced by cisplatin treatment.
Taken together, these results show that genotoxic stress activates p53-mediated transcription of apoptotic genes likely through HIPK2 kinase activity on p53Ser46 that renders p53 more resistant to in vivo ubiquitination by MDM2.
Discussion
The tumor suppressor p53 induces cell death by apoptosis in response to various stresses, such as oncogene activation or DNA damage (Giaccia and Kastan, 1998; Lakin and Jackson, 1999) . The loss of p53 tumor-suppressor activity, either by mutation/deletion of the TP53 gene or by inhibition of the p53 protein, favors the development of cancer (Gottlieb and Oren, 1996) . Thus, regulation of p53 stability and activity and its control on cell cycle and apoptosis are central to the problem of human tumorigenesis. The recently identified function of HIPK2 as an activator of p53 (Wang et al., 2001; D'Orazi et al., 2002; Hofmann et al., 2002; Kim et al., 2002) raised the possibility that HIPK2 might play an important role in the regulation of p53 apoptotic function. Indeed, in the present study, we demonstrate the involvement of HIPK2 in the rescue of a transcriptionally active p53 from MDM2 inhibition. We show that HIPK2 prevents the MDM2-mediated cytoplasmic shuttling and ubiquitination of p53, in vitro and in vivo following genotoxic stress, neutralizing its destabilization. Moreover, HPK2 is also able to change the interaction between MDM2 and p53. By these processes, HIPK2 is able to recover the p53 apoptotic function. Figure 5 Cisplatin-mediated HIPK2 induction relives p53 inhibition by MDM2. (a) Western blot analyses of HIPK2, MDM2, p53, and p53Ser46 phosphorylation on total cell proteins from RKO cells transfected with MDM2 expression vector, using the lipofectaminePlus method, and treated with cisplatin (5 mg/ml) for 24 h. Equal amount of proteins was separated on a denaturing SDS-PAGE and immunoblot analysis was performed using specific antibodies. Blots were reprobed with antitubulin to ensure equivalence of loading. (b) Western blot analysis of RKO cells treated with cisplatin (5 mg/ml) for 24 h and with the proteasome inhibitor MG132 (10 mM) for 12 h. Equal amount of proteins was separated on a denaturing SDS-PAGE, and immunoblot analysis was performed using specific polyclonal anti-Ser46 and monoclonal anti-p53 (DO1) antibodies. (c) Control RKO (pSuper)-or HIPK2-interfered (pSuper-HIPK2) cells were transfected with MDM2 vector and treated with cisplatin, as above. Subsequently, cells were treated with the proteasome inhibitor MG132 (10 mm) for 12 h. Equal amount of proteins was subjected to Western blot analysis with anti-p53 polyclonal antibody (FL393). The positions of the p53-ubiquitin (p53-Ub n ) conjugates are indicated. (d) Induction of luciferase activity on RKO cells transfected with MDM2 expression vector, using the lipofectaminePlus method, along with the bax-, PIG3-, and Noxa-luciferase reporter vectors, and treated with cisplatin (5 mg/ml) for 24 h. All transfections were performed in duplicate. Results are the mean of three different experiment7s.d.
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The MDM2 protein is a negative regulator of p53: indeed both proteins participate in an autoregulatory feedback loop (Picksley and Lane, 1993; Wu et al., 1993) . After binding to p53, MDM2 inhibits its transcriptional activity (Momand et al., 1992) , favors its nuclear export (Freedman and Roth et al., 1998; Tao and Levine, 1999) , and stimulates its degradation (Haupt et al., 1997; Kubbutat et al., 1997) . The importance of MDM2 in controlling p53 activity is demonstrated by the mdm2-knockout mice. Their embryos die very early during gestation, but additional deletion of p53 rescues them from death (Jones et al., 1995; Montes de Oca Luca et al., 1995) . Cell growth or cell death depends, to a large extent, on fine-tuning of the p53-MDM2 interaction. Overexpression of MDM2 blocks p53-mediated cell-cycle arrest and apoptosis (Chen et al., 1996; Haupt et al., 1996) , and this should have negative consequences for cells, because it diminishes their ability to activate the p53 pathway under stress conditions. Indeed, in different types of tumors, MDM2 overexpression favors uncontrolled cell proliferation (Leite et al., 2001; Polsky et al., 2001; Eymin et al., 2002) .
As MDM2 controls p53 activity, inhibition of such association allows an immediate p53-mediated response (Prives, 1998) . One of the mechanisms that control the MDM2/p53 interaction is DNA damage-induced phosphorylation of different p53 residues (e.g. Ser15, Thr18, Ser20), which hinders p53 binding to MDM2. After stress, modification of the p53 protein prevents or disrupts the MDM2/p53 interaction, which results in p53 activation (Craig et al., 1999; Sakaguchi et al., 2000) . Hence, protein kinases involved in phosphorylating p53 sites that regulate its interaction with MDM2 are particularly useful in order to better understand the mechanisms of p53 activation. Here we report that HIPK2, a kinase that activates p53 through its specific phosphorylation at Ser46 (D'Orazi et al., 2002; Hofmann et al., 2002) , can efficiently rescue p53 transcriptional activity and apoptosis from MDM2 inhibition. One possible explanation for this action might be that HIPK2 phosphorylation at Ser46 renders p53 more resistant to inhibition by MDM2, maintaining its capacity to transactivate responsive genes and induce apoptosis, in agreement with the model of Prives and coworkers (Shieh et al., 1997; Prives, 1998) , where phosphorylation at the N-terminal sites of p53 (where Ser46 resides) may prevent the inhibitory effect of MDM2 and render p53 active.
One other important mechanism by which MDM2 negatively regulates p53 is by promoting its degradation through the ubiquitin-proteasome pathway (Haupt et al., 1997; Kubbutat et al., 1997) . The nuclear export of p53 is important for this process. In this regard, we show that HIPK2 protects p53 from nuclear export and ubiquitination by MDM2. We also show that, in the presence of HIPK2, MDM2 is no longer able to interact with p53. These findings provide a mechanistic explanation for the cooperation between p53 and HIPK2 in the presence of MDM2. Thus, the maintenance of nuclear p53 by HIPK2, overcoming MDM2 negative effects, enhances its transcriptional activity. Since p53 functions as a transcription factor, it must be in the nucleus to be fully active. Indeed, sequestration of p53 in the cytoplasm of some tumors suggests that this localization of p53 may represent a nonmutational mechanism of inactivation (Moll et al., 1992) . The physiological relevance of the cooperation between p53 and HIPK2 in the presence of MDM2 is shown after genotoxic stress. We have recently demonstrated that HIPK2 activates p53 apoptotic function, through phosphorylation of Ser46, after treatment with cisplatin. The relevance of HIPK2 on p53 activity was demonstrated with HIPK2 gene silencing by RNA interference, which efficiently reduced p53-mediated apoptosis (Di Stefano et al., 2004) . We show here that one possible mechanism, leading to the activation of the HIPK2/p53 pathway, is the reduction of p53 ubiquitination mediated by MDM2. Thus, only in HIPK2-interfered cells p53 is ubiquitinated by MDM2. How HIPK2 prevents the ubiquitination of p53 by MDM2 is still a matter of speculation and further investigations. A p53-mediated downregulation of MDM2 expression was observed in Saos2 cells overexpressing HIPK2 and p53 (Wang et al., 2001, and present paper) . This MDM2 downregulation could depend on multiple mechanisms including p53 post-translational modifications and additional protein/ protein interactions. Therefore, a direct interaction between HIPK2 and MDM2 cannot be excluded. Further experiments are under evaluation to better elucidate this hypothetical regulatory mechanism.
In conclusion, in this study, we have shown that the activation of the HIPK2/p53 pathway plays an important role in the inhibition of the MDM2/p53 interaction rescuing p53 apoptotic function. Among the many genes that appear to play a role in the regulation of apoptosis, p53 has emerged as one of the leading 'death star' (Vousden, 2000) . In this regard, molecules such as HIPK2 that appear to regulate specifically the p53 apoptotic pathway, and that we show to regulate also the MDM2/p53 complex, might be useful as attractive new anticancer strategies aimed at activating the p53 apoptotic pathway in tumor that overexpress MDM2 but retain wild-type p53 (Chene, 2003) .
Materials and methods
Cells, transfection, and treatments
H1299 lung adenocarcinoma (p53 null), Saos2 osteosarcoma (p53 null), and RKO colon cancer cells (wtp53) were grown in RPMI-1640 medium (GIBCO-BRL, Life Technology, Grand Island, NY, USA) supplemented with 10% heat-inactivated fetal bovine serum (GIBCO-BRL).
Transient transfection assays were performed using the BES or the lipofectaminePlus (Invitrogen) methods, as described earlier (D'Orazi et al., 2002) . The amount of plasmid DNA was equalized in each sample by supplementing with empty plasmid. Expression vectors used in this study were: pCAG3.1wtp53, p53S46A (kindly provided by E Appella, NIH, Bethesda, USA), pCMV-MDM2, HIPK2-Flag, K221R-Flag (HIPK2 kinase dead mutant).
Cells treatments: Cisplatin was used at 5 mg/ml; MG132 proteasome inhibitor (Biomol Research Laboratories, PA, USA) was maintained in DMSO and used at a final concentration of 10 mM.
Transactivation assay
Cells were transiently transfected using BES or lipofectaminePlus (Invitrogen) methods, with the luciferase reporter gene driven by the p53-dependent promoters bax (Miyashita and Reed, 1995) , PIG-3 (Polyak et al., 1997), or Noxa (Oda et al., Science 2000; kindly provided by T Taniguchi, University of Tokyo, Japan). Transfection efficiencies were normalized with the use of a cotransfected b-galactosidase construct, and luciferase activity was assayed as described previously (D'Orazi et al., 2002) .
Western blotting and immunoprecipitation analyses
For ubiquitination assay, cells were transfected with the indicated vectors and 24 h later treated with the proteasome inhibitor MG132 (10 mM) for additional 12 h. Total cell lysates were prepared by incubating cell pellets for 30 min on ice in lysis buffer (2 mM Tris-HCl pH 7.5; 5 mM EDTA; 150 mM NaCl; 1% sodium dehoxycolate; 0.025% SDS) plus protease inhibitors. Equal amounts of protein were immunoprecipitated with anti-p53 antibodies (DO1 and Ab1801, Santa Cruz Biotechnology) preadsorbed to protein G-agarose (Pierce). Immunocomplexes were collected by centrifugation, separated by 9% SDS-PAGE, and blotted onto nitrocellulose membrane (Bio-Rad, Hercules, CA, USA). For Western blotting, membranes were incubated with anti-p53 polyclonal antibody (FL393, Santa Cruz Biotechnology), anti-Flag monoclonal antibody (Upstate Biotechnology), anti-MDM2 monoclonal antibody (Ab1, Santa Cruz), anti-HIPK2 rabbit antiserum (kindly provided by ML Schmitz, University of Bern, Switzerland), anti-phospho-p53-Ser46 rabbit polyclonal antibody (Cell Signaling), and anti b-gal monoclonal antibody (Sigma, Bio-Sciences, St Louis, MO, USA). Immunoreactivity was detected by ECL chemiluminescence reaction kit (Amersham Corp., Arlington Heights, IL, USA).
